PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASE OR CACHEXIA COMPRISING, AS ACTIVE INGREDIENT, MIRNA LOCATED IN DLK1 -DIO3 CLUSTER OR VARIANT THEREOF

• Main Authors: LEE KWANG-PYO, SHIN YEO-JIN, KWON KI-SUN, LEE BO-RA, LEE SEUNG-MIN
• Format: Patent
• Language: Chinese; English
• Published: 04.12.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The present invention relates to a pharmaceutical composition for preventing or treating a muscular disease or cachexia, comprising, as an active ingredient, a miRNA located in Dlk1-Dio3 cluster or avariant thereof. In the present invention, it has been found that expression of miRNAs located in the Dlk1-Dio3 cluster is decreased as age increases. In particular, in a case where most of the miRNAsare over-expressed in fully differentiated myotubes, it has been confirmed that the diameter of the myotubes increases. In addition, also in a tumor-induced cachexia mouse model, it has been confirmed that cachexia was improved by inhibiting Atrogin-1 protein. Accordingly, the miRNA located in the Dlk1-Dio3 cluster or a variant thereof can be usefully utilized for the treatment and prevention ofan Atrogin-1 - dependent muscular disease and cachexia. 本发明涉及用于预防或治疗肌肉疾病或恶病质的药物组合物，所述药物组合物包含位于Dlk1-Dio3簇中的miRNA或其变体作为活性成分。在本发明中，发现位于Dlk1-Dio3簇中的miRNA的表达随年龄增加而下降。特别地，在大部分的miRNA在完全分化的肌管中过表达的情况下，已经确认肌管的直径增加。此外，同样在肿瘤引起的恶病质小鼠模型中，已经确